Ajay Jain, MD
Pulmonary Disease · Houston, TXNPI 1063426674
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.7% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2022 at $13,097 and has fallen 65.1% since, to $4,577 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 905 payments — averaging $52.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$31K
- GSK$3K
- Inspire Medical Systems, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$991
- plus $7K from 42 others
Across 51 payments — averaging $6643.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$238K
- Sanofi US Services Inc.$54K
- AstraZeneca$47K
What the payments were for
- Speaking & faculty fees$27,00057%
- Travel & lodging$1,0352%
- Food & beverage$19,24241%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$25,383
- BREZTRI AEROSPHERE$2,900
- Inspire Upper Airway Stimulation System$1,669
- FASENRA$657
- DUPIXENT$504
- AIRSUPRA$421
- TEZSPIRE$296
- UPTRAVI$262
- Inspire$256
- FARXIGA$247
- remede System$202
- OPSUMIT$140
- Ohtuvayre$125
- Da Vinci Surgical System$123
- XARELTO$122
- NUCALA$122
- Livmarli$121
How this compares
$47,448 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 48 | $626,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 764 | $616,295 |
| OpsumitMacitentan | 17 | $205,563 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 212 | $160,558 |
| AdempasRiociguat | 12 | $155,200 |
| Breo ElliptaFluticasone/Vilanterol | 212 | $99,428 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 131 | $73,686 |
| Fasenra PenBenralizumab | 12 | $64,910 |
| NucalaMepolizumab | 17 | $62,918 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $45,435 |
| Dupixent PenDupilumab | 12 | $43,922 |
| Ambrisentan | 16 | $26,342 |
| XareltoRivaroxaban | 35 | $24,430 |
| EliquisApixaban | 28 | $19,693 |
| Spiriva RespimatTiotropium Bromide | 30 | $17,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala | $3,167 | $852,3271,124 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $113 | $689,500149 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,641 | $205,56317 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $31,154 | $174,034246 claims |
| BayerAdempas | $99 | $155,20012 claims |
| Johnson & JohnsonXarelto | $413 | $24,43035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.